Additionally, the 36-month beta value for MIRM is 1.15. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MIRM is 36.61M and currently, short sellers hold a 23.42% ratio of that float. The average trading volume of MIRM on April 26, 2024 was 496.81K shares.
MIRM) stock’s latest price update
Mirum Pharmaceuticals Inc (NASDAQ: MIRM)’s stock price has soared by 1.96 in relation to previous closing price of 24.02. Nevertheless, the company has seen a gain of 3.90% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-15 that Mirum’s (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
MIRM’s Market Performance
MIRM’s stock has risen by 3.90% in the past week, with a monthly drop of -1.73% and a quarterly drop of -6.56%. The volatility ratio for the week is 3.93% while the volatility levels for the last 30 days are 3.61% for Mirum Pharmaceuticals Inc The simple moving average for the last 20 days is -1.48% for MIRM’s stock, with a simple moving average of -12.93% for the last 200 days.
Analysts’ Opinion of MIRM
Many brokerage firms have already submitted their reports for MIRM stocks, with Stifel repeating the rating for MIRM by listing it as a “Buy.” The predicted price for MIRM in the upcoming period, according to Stifel is $48 based on the research report published on April 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MIRM reach a price target of $58, previously predicting the price at $60. The rating they have provided for MIRM stocks is “Buy” according to the report published on December 18th, 2023.
JP Morgan gave a rating of “Overweight” to MIRM, setting the target price at $37 in the report published on November 20th of the previous year.
MIRM Trading at -8.12% from the 50-Day Moving Average
After a stumble in the market that brought MIRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.13% of loss for the given period.
Volatility was left at 3.61%, however, over the last 30 days, the volatility rate increased by 3.93%, as shares sank -2.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.78% lower at present.
During the last 5 trading sessions, MIRM rose by +3.90%, which changed the moving average for the period of 200-days by -7.97% in comparison to the 20-day moving average, which settled at $24.83. In addition, Mirum Pharmaceuticals Inc saw -17.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRM starting from BJERKHOLT ERIC, who purchase 2,000 shares at the price of $24.80 back on Mar 27 ’24. After this action, BJERKHOLT ERIC now owns 14,000 shares of Mirum Pharmaceuticals Inc, valued at $49,600 using the latest closing price.
Radovich Peter, the PRESIDENT AND COO of Mirum Pharmaceuticals Inc, sale 4,303 shares at $25.80 during a trade that took place back on Mar 25 ’24, which means that Radovich Peter is holding 29,013 shares at $111,017 based on the most recent closing price.
Stock Fundamentals for MIRM
Current profitability levels for the company are sitting at:
- -0.57 for the present operating margin
- 0.76 for the gross margin
The net margin for Mirum Pharmaceuticals Inc stands at -0.86. The total capital return value is set at -0.19. Equity return is now at value -82.37, with -32.20 for asset returns.
Based on Mirum Pharmaceuticals Inc (MIRM), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.23. The debt to equity ratio resting at 1.24. The interest coverage ratio of the stock is -13.4.
Currently, EBITDA for the company is -98.33 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 6.24. The receivables turnover for the company is 2.74for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
In conclusion, Mirum Pharmaceuticals Inc (MIRM) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
